Abstract
Objectives To describe medication management of children diagnosed with anxiety and depression by primary care providers.
Study Design/Methods We performed a retrospective cross-sectional analysis of electronic health record (EHR) structured data. All visits for pediatric patients seen at least twice during a four-year period within a network of primary care clinics in Northern California were included. Descriptive statistics summarized patient variables and most commonly prescribed medications. For each subcohort (anxiety, depression, and both (anxiety+depression)), logistic regression models examined the variables associated with medication prescription.
Results Of all patients (N=93,025), 2.8% (n=2635) had a diagnosis of anxiety only, 1.5% (n=1433) depression only, and 0.79% (n=737) both anxiety and depression (anxiety+depression); 18% of children with anxiety and/or depression had comorbid ADHD. A total of 14.0% with anxiety (n=370), 20.3% with depression (n=291), and 47.5% with anxiety+depression (n=350) received a psychoactive non-stimulant medication. For anxiety only and depression only, sertraline, citalopram, and fluoxetine were most commonly prescribed. For anxiety+depression, citalopram, sertraline, and escitalopram were most commonly prescribed. The top prescribed medications also included benzodiazepines. Logistic regression models showed that older age and having developmental or mental health comorbidities were independently associated with increased likelihood of medication prescription for children with anxiety, depression, and anxiety+depression. Insurance type and sex were not associated with medication prescription.
Conclusions PCPs prescribe medications more frequently for patients with anxiety+depression than for patients with either diagnosis alone. Medication choices generally align with current recommendations. Future research should focus on the use of benzodiazepines due to safety concerns in children.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Partial funding was provided by Developmental-Behavioral Pediatrics Fellowship Training from the Maternal Child Health Bureau of Health Resources and Services Administration T77MC09796.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Stanford University Institutional Review Board (IRB)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: Partial funding was provided by Developmental-Behavioral Pediatrics Fellowship Training from the Maternal Child Health Bureau of Health Resources and Services Administration T77MC09796.
Author Conflict of Interest: None
Data Availability
The authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary materials.